524731 — Jenburkt Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹3.09bn
- IN₹2.53bn
- IN₹1.37bn
- 100
- 48
- 55
- 82
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,226 | 1,189 | 1,093 | 1,240 | 1,367 |
Cost of Revenue | |||||
Gross Profit | 850 | 847 | 784 | 913 | 1,022 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 990 | 1,014 | 915 | 986 | 1,086 |
Operating Profit | 236 | 174 | 178 | 254 | 281 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 266 | 211 | 216 | 299 | 329 |
Provision for Income Taxes | |||||
Net Income After Taxes | 198 | 149 | 165 | 223 | 246 |
Net Income Before Extraordinary Items | |||||
Net Income | 198 | 149 | 165 | 223 | 246 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 198 | 149 | 165 | 223 | 246 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 43.2 | 32.4 | 36 | 48.3 | 55.7 |
Dividends per Share |